A tumor is not a solid lump of identical cancer cells. It’s a complex, disorganized mini-organ containing cancer cells, immune cells, blood vessels, structural fibers, fluid, and often a core of dead tissue. The cancer cells themselves sometimes make up only a fraction of the total mass. The rest is a chaotic ecosystem called the tumor microenvironment, and understanding what’s in it helps explain why tumors behave the way they do.
Cancer Cells Are Only Part of the Picture
The cells that are actually cancerous, the ones dividing out of control, share space with a large population of non-cancerous cells. Structural cells called fibroblasts produce the fibrous scaffold that holds the tumor together. Immune cells flood in from the bloodstream. Blood vessel cells line the tumor’s own makeshift circulatory system. In many solid tumors, these supporting players collectively rival or even outnumber the malignant cells themselves.
What makes the cancer cells especially unpredictable is that they’re not all the same. Most tumors start from a single mutated cell, but as that cell divides, its offspring accumulate different mutations over time. The result is a patchwork of genetically distinct subpopulations, called subclones, living side by side in the same tumor. A biopsy taken from one region of a breast tumor, for example, can reveal mutations that are completely absent in another region just centimeters away. Research using single-cell sequencing on breast tumors has shown that multiple mutated clones can evolve within the ducts before the cancer even becomes invasive, with some subclones more prevalent in the aggressive, spreading regions. This internal genetic diversity is one of the main reasons tumors can resist treatment: a drug that kills one subclone may leave another untouched.
The Immune Cells Trapped Inside
Your immune system does recognize tumors as a threat, and it sends reinforcements. Inside most solid tumors, you’ll find a mix of immune cells: killer T cells designed to destroy abnormal cells, helper T cells that coordinate the immune response, natural killer cells, B cells, and various types of antigen-presenting cells that act as scouts, identifying threats and alerting the rest of the immune system.
The problem is that tumors fight back. They recruit their own team of immunosuppressive cells that actively shut down the immune response from within. Tumor-associated macrophages, which are immune cells that have essentially been reprogrammed by the tumor, work alongside regulatory T cells and another group called myeloid-derived suppressor cells to block the killer T cells from doing their job. These suppressive cells interfere with immune activation on multiple levels, creating an environment where the immune system is present but largely paralyzed. This internal tug-of-war between pro-immune and anti-immune forces is exactly what newer immunotherapy drugs try to tip in the patient’s favor.
A Tangled, Leaky Blood Supply
Tumors can’t grow beyond a few millimeters without building their own blood supply, a process called angiogenesis. But the blood vessels inside a tumor look nothing like the orderly network in healthy tissue. Normal blood vessels follow a clear hierarchy: arteries branch into smaller arterioles, then into tiny capillaries, then into venules and veins, all lined with tightly connected cells and reinforced by support cells called pericytes. Tumor vessels skip this blueprint entirely.
Because the tumor constantly pumps out signals demanding new blood vessel growth, the vessels that form never properly mature. They lack the normal division into arterioles, capillaries, and venules. Their diameter varies wildly. The cells lining these vessels have gaps between them, making the vessels abnormally leaky. The support cells that normally wrap around blood vessels are partially detached, and the basement membrane (a thin structural layer that reinforces the vessel wall) is uneven and loosely attached. Blood flow through this disorganized plumbing is chaotic and unpredictable, which creates a cascade of problems inside the tumor.
Fluid Under Pressure
One direct consequence of those leaky blood vessels is a buildup of fluid. In healthy tissue, the pressure of fluid between cells sits close to zero, roughly at atmospheric pressure. Inside a solid tumor, that pressure typically climbs to 10 to 40 mmHg, and in aggressive melanomas, it has been recorded as high as 100 mmHg. This elevated pressure comes from plasma leaking out of defective vessels with nowhere to drain, since tumors also tend to have poorly functioning lymphatic vessels that would normally carry excess fluid away.
This pressurized fluid does more than cause swelling. It creates an outward push that can carry cancer cells and signaling molecules into surrounding healthy tissue. It also makes it harder for drugs delivered through the bloodstream to penetrate into the tumor’s interior, because the high internal pressure opposes the inward flow of fluid from blood vessels. This is one reason why large, solid tumors can be difficult to treat with chemotherapy alone.
Dead Tissue at the Center
The chaotic blood supply means some regions inside the tumor receive almost no oxygen. In fast-growing tumors, this oxygen deprivation is worst at the center, where cells are farthest from any functioning blood vessel. When oxygen drops below survivable levels, cells die in large numbers, leaving behind a necrotic core of dead tissue.
This process is well-documented in glioblastoma, one of the most aggressive brain cancers. Blood clots form inside tumor vessels, cutting off supply to nearby tissue. Cells that can still move begin migrating away from the oxygen-starved zone, creating a distinctive ring of densely packed cells around the dead center. Meanwhile, the necrotic core expands. In smaller vessel blockages, these dead zones can start at around 30 to 60 micrometers across and form within days. When the distance between functioning vessels is greater than 150 to 200 micrometers, the necrotic areas grow substantially larger. Not every tumor develops a necrotic core, but in large or rapidly growing ones, it’s common. The presence of necrosis on imaging or biopsy is often a sign of a more aggressive cancer.
The Structural Scaffold
Holding all of this together is a dense web of proteins and fibers called the extracellular matrix. Think of it as the scaffolding of the tumor. It’s made primarily of collagen fibers, along with other structural proteins that provide physical support and influence how cells behave. In many tumors, this matrix is stiffer and denser than the matrix found in normal tissue, which is part of why tumors often feel like hard lumps.
The matrix isn’t just passive scaffolding. It actively shapes how the tumor grows. Cancer cells remodel the fibers around them to create pathways for invasion into surrounding tissue. The stiffness of the matrix can also affect how cancer cells respond to signals, sometimes promoting more aggressive behavior. Fibroblasts within the tumor, often called cancer-associated fibroblasts, are the main producers of this matrix, and they tend to be far more active than normal fibroblasts, constantly depositing new material.
How Benign Tumors Differ Inside
Not all tumors are cancerous. Benign tumors contain many of the same basic components, but their internal organization is fundamentally different. Most benign tumors are surrounded by a capsule of fibrous connective tissue that cleanly separates the tumor cells from the normal tissue outside. The cells inside tend to be more uniform, dividing slowly if at all, and they don’t invade through the capsule into surrounding structures. They typically lack the chaotic blood vessel networks, high internal pressure, and necrotic cores that characterize aggressive malignant tumors.
What Pathologists Look for Inside
When a tumor is biopsied, pathologists examine its internal contents for specific clues. Special stains can highlight substances the tumor produces. A mucus-detecting stain, for instance, turns pink or red when it finds mucus inside lung cancer cells, pointing to a specific subtype called adenocarcinoma. Immune-based stains use antibodies that bind to unique proteins on or inside the cancer cells, helping identify exactly what type of cancer it is and which treatments it might respond to.
Beyond identifying cell types, pathologists measure how fast the cells are dividing by counting the percentage of cells caught in the act of copying their DNA. They also assess whether the cells contain a normal or abnormal amount of DNA overall. Tumors packed with rapidly dividing cells that carry abnormal DNA content tend to be more aggressive. Together, these internal characteristics help determine how the cancer is staged and what treatment approach is most likely to work.